Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations

Anupong Tangpeerachaikul(Covalent Associates (United States)), Henry E. Pelish(Covalent Associates (United States))
Molecular Cancer Therapeutics
April 29, 2025
Cited by 4


Related Papers